Evidence map›Paper›PMID 38336826›Full record

Observational studyScientific reports2024

Centromeric AA motif in KIR as an optimal surrogate marker for precision definition of alloimmune reproductive failure.

Raquel Gil Laborda, Edgard Rodríguez de Frías, Nabil Subhi-Issa, Elena Carrillo de Albornoz, Elena Meliá, Marcos Órdenes, Victoria Verdú, Juan Vidal, Esther Suárez, Isabel Santillán and 23 more

Open access · goldAbstract readObservational Study
In one paragraph

Observational study in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.2field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

33 authors at 7 institutions in 1 country.

Raquel Gil LabordaDepartment of Immunology, IML and IdISSC, Hospital Clínico San Carlos, Madrid, Spain.
Edgard Rodríguez de FríasDepartment of Immunology, IML and IdISSC, Hospital Clínico San Carlos, Madrid, Spain.
Nabil Subhi-IssaDepartment of Immunology, IML and IdISSC, Hospital Clínico San Carlos, Madrid, Spain.
Elena Carrillo de AlbornozWoman Unit, Hospital Ruber Internacional, Madrid, Spain.
Elena MeliáWoman Unit, Hospital Ruber Internacional, Madrid, Spain.
Marcos ÓrdenesAssisted Reproductive Unit, Hospital Ruber Internacional, Madrid, Spain.
Victoria VerdúClínica GINEFIV, Madrid, Spain.
Juan VidalWoman Unit, Hospital Ruber Internacional, Madrid, Spain.
Esther SuárezWoman Unit, Hospital Ruber Internacional, Madrid, Spain.
Isabel SantillánClínica GINEFIV, Madrid, Spain.
Daniel OrdóñezWoman Unit, Hospital Ruber Internacional, Madrid, Spain.
David Pintado-VeraSterility and Infertility Unit, Hospital Quiron Salud, Pamplona, Spain.
Victoria González VillafáñezClínica GINEFIV, Madrid, Spain.
Ángel LorenzoWoman Unit, Hospital Ruber Internacional, Madrid, Spain.
Manuel FariñasClínica Hemomadrid, Madrid, Spain.
Mario Rodríguez-PaínoClínica Hemomadrid, Madrid, Spain.
María Núñez BeltránDepartment of Immunology, IML and IdISSC, Hospital Clínico San Carlos, Madrid, Spain.
Áurea García SegoviaSanitas Assisted Reproduction Unit, Clínica Sanitas Millenium Alcobendas, Madrid, Spain.
Ainhoa Del OlmoDepartment of Immunology, IML and IdISSC, Hospital Clínico San Carlos, Madrid, Spain.
Fernando Martín CañadasInstituto Malavé de Ginecología, Málaga, Andalucía, Spain.
Rosa DaurelioClínica GINEFIV, Madrid, Spain.
Alfonso de la FuenteInstituto Europeo de Fertilidad (IEF), Madrid, Spain.
José Manuel González CasbasInstituto Europeo de Fertilidad (IEF), Madrid, Spain.
Vega CabezueloWoman Unit, Hospital Ruber Internacional, Madrid, Spain.
Francisco Ros BerruezoAssisted Reproduction Unit in HM Fertility Center, Gabinete Velázquez, Madrid, Spain.
Miguel Ángel Moreno HidalgoCentro de Trasfusión de la Comunidad de Madrid, Madrid, Spain.
Silvia IniestaAssisted Reproductive Unit, Hospital Ruber Internacional, Madrid, Spain.
Beatriz BuenoAssisted Reproductive Unit, Hospital Ruber Internacional, Madrid, Spain.
Álvaro Martínez AceraWoman Unit, Hospital Ruber Internacional, Madrid, Spain.
Alexandra IzquierdoDepartment of Immunology, IML and IdISSC, Hospital Clínico San Carlos, Madrid, Spain.
José Luis VicarioCentro de Trasfusión de la Comunidad de Madrid, Madrid, Spain.
Miguel Fernández-ArqueroDepartment of Immunology, IML and IdISSC, Hospital Clínico San Carlos, Madrid, Spain.
Silvia Sánchez-RamónClinical Immunology Unit, Hospital Ruber Internacional, Madrid, Spain. silvia.sanchez@ruberinternacional.es.
Hospital Ruber Internacional · ESHospital Clínico San Carlos · ESClínica Rementería · ESInstituto de Fermentaciones Industriales · ESComunidad de Madrid · ESLight Prescriptions Innovators (Spain) · ESCasa de Velázquez · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Throughout pregnancy, the decidua is predominantly populated by NK lymphocytes expressing Killer immunoglobulin-like receptors (KIR) that recognize human leukocyte antigen-C (HLA-C) ligands from trophoblast cells. This study aims to investigate the association of KIR-HLA-C phenotypes in couples facing infertility, particularly recurrent pregnancy loss (RPL) and recurrent implantation failure (RIF), in comparison to a reference population and fertile controls. This observational, non-interventional retrospective case-control study included patients consecutively referred to our Reproductive Immunology Unit from 2015 to 2019. We analyzed the frequencies of KIR and HLA-C genes. As control groups, we analyzed a reference Spanish population for KIR analysis and 29 fertile controls and their male partners for KIR and HLA-C combinations. We studied 397 consecutively referred women with infertility and their male partners. Among women with unexplained RPL (133 women) and RIF (176 women), the centromeric (cen)AA KIR genotype was significantly more prevalent compared to the reference Spanish population (p = 0.001 and 0.02, respectively). Furthermore, cenAA was associated with a 1.51-fold risk of RPL and a 1.2-fold risk of RIF. Conversely, the presence of BB KIR showed a lower risk of reproductive failure compared to non-BB KIR (OR: 0.12, p < 0.001). Women and their partners with HLA-C1C1/C1C1 were significantly less common in the RPL-Group (p < 0.001) and RIF-Group (p = 0.002) compared to the control group. Moreover, the combination of cenAA/C1C1 in women with C1C1 partners was significantly higher in the control group than in the RPL (p = 0.009) and RIF (p = 0.04) groups, associated with a 5-fold increase in successful pregnancy outcomes. In our cohort, the cenAA KIR haplotype proved to be a more accurate biomarker than the classic AA KIR haplotype for assessing the risk of RPL and RIF, and might be particularly useful to identify women at increased risk among the heterogeneous KIR AB or Bx population. The classification of centromeric KIR haplotypes outperforms classical KIR haplotypes, making it a better indicator of potential maternal-fetal KIR-HLA-C mismatch in patients.

Indexed as

Abortion, HabitualInfertilityAmino Acid MotifsBiomarkersCase-Control StudiesFemaleHLA-C AntigensHumansMalePregnancyReceptors, KIRRetrospective StudiesBiomarkersHLA-C AntigensReceptors, KIRHLA-C Lymphocyte AntigenImmunoglobulin-Like ReceptorKiller CellNatural Killer CellsRecurrent Implantation FailureRecurrent Pregnancy LossUnexplained Recurrent Pregnancy Loss

Identifiers

PMID38336826
PMCPMC10858137
OpenAlexW4391679442

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.